1SAN Sanofi

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Paris, October 25, 2024

Q3 sales growth of 15.7% at CER and business EPS⁽¹⁾ of €2.86

• Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmed
• Pharma launches up 67.1% to €727 million, led by ALTUVIIIO, Nexviazyme and Rezurock
• Vaccines sales up 25.5%, boosted by phasing of flu sales, and by Beyfortus due to approved extra capacity
• Opella up 7.9%, driven by the Qunol acquisition
• Research and Development expenses grew 12.7%
• Selling, general and administrative expenses grew 6.4%, substantially below sales growth, having a positive impact on profitability
• Business EPS⁽¹⁾ of €2.86, +12.2% reported and +17.6% at CER and IFRS EPS of €2.25, +11.9% reported
  
  

Q3 pipeline progress

• Four regulatory approvals: Dupixent COPD (US, CN), Dupixent CRSwNP adolescents (US), and Sarclisa NDMM, TI (US)
• Four positive phase 3 data readouts: Dupixent BP, Dupixent CSU, tolebrutinib nrSPMS, and Sarclisa NDMM, TE

Opella (consumer healthcare)

• On October 21, Sanofi and CD&R entered exclusive negotiations to transfer a controlling stake of Opella.*
  
  

2024 business EPS⁽¹⁾ guidance

• On October 21, 2024, the 2024 business EPS⁽¹⁾ guidance was upgraded to growth of at least a low single-digit percentage at CER⁽²⁾ supported by the underlying strong business performance. This reflects the new scope of guidance excluding Opella detailed in the October 21, 2024 press release. Applying the average October 2024 exchange rates, the currency impact on 2024 business EPS⁽¹⁾ is estimated to be -5.5% to -6.5%.
  
  

Paul Hudson, Chief Executive Officer: “We reached almost 16% sales growth in the third quarter, illustrating the underlying strength of our portfolio. Our performance was boosted by the phasing of flu and Beyfortus, while we saw steady growth of 67% for our launch medicines as well as volume-driven growth by Dupixent. Dupixent is now approved as the first-ever biologic medicine to treat COPD across the EU, China, and the US allowing us to bring this innovative new treatment to hundreds of thousands of patients. Our pipeline-driven transformation continued to progress with the delivery of four new approvals and four positive phase 3 data readouts, including for tolebrutinib in secondary progressive multiple sclerosis, a disease with significant unmet medical need. We entered exclusive negotiations with CD&R on a controlling stake in Opella, allowing Sanofi to focus on innovative medicines and vaccines. Based on the strong business performance in the quarter, we recently upgraded our business EPS guidance. This momentum is already paving the way for the strong rebound we said we expected in 2025 business EPS.”

	Q3 2024	Change	Change at CER	YTD 2024	Change	Change at CER
IFRS net sales reported	€        13,438        m	+12.3%	+15.7%	€        34,647        m	+7.8%	+11.1%
IFRS net income reported	€        2,815        m	+11.5%	—	€        5,061        m	-15.0%	—
IFRS EPS reported	€        2.25	+11.9%	—	€        4.05	-14.9%	—
Free cash flow(3)	€        3,327        m	+79.5%	—	€        3,872        m	-22.3%	—
Business operating income	€        4,607        m	+14.4%	+19.9        %	€        10,263        m	+1.7%	+8.8%
Business net income(1)	€        3,585        m	+12.2%	+17.5        %	€        7,965        m	-1.3%	+5.5%
Business EPS(1)	€        2.86	+12.2%	+17.6%	€        6.37	-1.2%	+5.6%

Changes in net sales are expressed at constant exchange rates (CER) unless stated otherwise (definition in Appendix 7). (1) In order to facilitate an understanding of
operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 7). The
consolidated income statement for Q3 and YTD 2024 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in
Appendix 4. (2) Based on 2023 preliminary business EPS of €7.25 excluding Opella. (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 7). *The
proposed transaction is subject to finalization of definitive agreements, completion of the appropriate social processes and subject to customary closing conditions.

Attachment

• Press_Release